Argenta signs integrated services agreement with Pulmagen Therapeutics
Galapagos NV announced that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects.
Under the terms of the agreement, Argenta will be eligible to receive up to £6 million (€7 million) in fee-for-service payments over two years, with the possibility to extend. Building on its excellent reputation in respiratory diseases, Argenta will perform chemistry, biology, ADMET/PK and pharmacology services to bring two respiratory projects to pre-clinical status.
"We are pleased that Pulmagen has come to Argenta for two projects of such substantial scope. These projects will make a strong contribution to the service operations' performance in 2011," said Dr Chris Newton, SVP Services of Galapagos. "Today's agreement also demonstrates how well positioned Argenta is to perform longer term, integrated projects for its clients."
The deal with Argenta is part of a discovery and development collaboration that Pulmagen has established with Chiesi Farmaceutici S.p.A., a private Italian Group, with focus in respiratory diseases. The purpose of the discovery programs is to identify new compounds with anti-inflammatory potential to be developed for respiratory conditions characterized by a high unmet medical need such as COPD and cystic fibrosis. The terms of the collaboration between Pulmagen and Chiesi are not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
